A molecular model for cocaine binding by the immunotherapeutic human/mouse chimeric monoclonal antibody 2E2

European Journal of Medicinal Chemistry

Volumn 45, Issue 6, 2010, Pages 2291-2298

  Lape, Michael ^a   Paula, Stefan ^a   Ball Jr , William J ^b  

^a NORTHERN KENTUCKY UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody; Cocaine; Drug addiction; Homology modeling; Immunotherapy; Molecular docking

Indexed keywords

AMINO ACID; COCAINE; GLUTAMIC ACID; LEUCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2E2; SERINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; COMPUTER MODEL; GENETIC TRANSFECTION; HEAVY CHAIN; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; LIGHT CHAIN; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; POINT MUTATION; SCORING SYSTEM; TANDEM MASS SPECTROMETRY; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; COCAINE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN VARIABLE REGION; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POINT MUTATION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY;

EID: 77950862827     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.02.004     Document Type: Article

References (36)

1. U.S. Dept. H.H.S. The NSDUH Report. Cocaine use: 2002 and 2003 (2005), National Survey on Drug Use and Health
2. U.S. Dept. H.H.S., Trends in Cocaine Treatment Admissions, by State: 1992-2002, in: The DASIS Report; 2005.
3. U.S. Dept. H.H.S. Results from 2008 National Survey on drug use and health: Detailed Tables (2008), Substance Abuse and Mental Health Services Administration (SAMHAS)
4. Elkashef A., Biswas J., Acri J.B., and Vocci F. Biotechnology and the treatment of addictive disorders: new opportunities. BioDrugs 21 (2007) 259-267
5. Nestler E.J. Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends in Pharmacological Sciences 25 (2004) 210-218
6. Preti A. New developments in the pharmacotherapy of cocaine abuse. Addiction Biology 12 (2007) 133-151
7. Kantak K.M. Vaccines against drugs of abuse: a viable treatment option?. Drugs 63 (2003) 341-352
8. Kosten T.R., Rosen M., Bond J., Settles M., Roberts J.S., Shields J., Jack L., and Fox B. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20 (2002) 1196-1204
9. Moreno A.Y., and Janda K.D. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacology, Biochemistry, and Behavior 92 (2009) 199-205
10. Martell B.A., Mitchell E., Poling J., Gonsai K., and Kosten T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry 58 (2005) 158-164
11. LeSage M.G., Keyler D.E., and Pentel P.R. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. The AAPS Journal 8 (2006) E65-E75
12. Paula S., Tabet M.R., Farr C.D., Norman A.B., and Ball Jr. W.J. Three-dimensional quantitative structure-activity relationship modeling of cocaine binding by a novel human monoclonal antibody. Journal of Medicinal Chemistry 47 (2004) 133-142
13. Norman A.B., Tabet M.R., Norman M.K., Buesing W.R., Pesce A.J., and Ball W.J. A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. The Journal of Pharmacology and Experimental Therapeutics 320 (2007) 145-153
14. Norman A.B., Norman M.K., Buesing W.R., Tabet M.R., Tsibulsky V.L., and Ball W.J. The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. The Journal of Pharmacology and Experimental Therapeutics 328 (2009) 873-881
15. Pozharski E., Moulin A., Hewagama A., Shanafelt A.B., Petsko G.A., and Ringe D. Diversity in hapten recognition: structural study of an anti-cocaine antibody M82G2. Journal of Molecular Biology 349 (2005) 570-582
16. Bork P., Holm L., and Sander C. The immunoglobulin fold. Structural classification, sequence patterns and common core. Journal of Molecular Biology 242 (1994) 309-320
17. Schiffer M., Girling R.L., Ely K.R., and Edmundson A.B. Structure of a lambda-type Bence-Jones protein at 3.5-A resolution. Biochemistry 12 (1973) 4620-4631
18. Ramachandran G.N., and Sasisekharan V. Conformation of polypeptides and proteins. Advances in Protein Chemistry 23 (1968) 283-438
19. Paula S., Monson N., and Ball Jr. W.J. Molecular modeling of cardiac glycoside binding by the human sequence monoclonal antibody 1B3. Proteins 60 (2005) 382-391
20. Rasmussen B.S., Pedersen J.M., Sorensen J., Egebjerg J., Schiott B., Mortensen K.K., and Skrydstrup T. Enantioselective proteins: selection, binding studies and molecular modeling of antibodies with affinity towards hydrophobic BINOL derivatives. Chembiochem 8 (2007) 1974-1980
21. Obungu V.H., Gelfanova V., Rathnachalam R., Bailey A., Sloan-Lancaster J., and Huang L. Determination of the mechanism of action of anti-FasL antibody by epitope mapping and homology modeling. Biochemistry 48 (2009) 7251-7260
22. Eldridge M.D., Murray C.W., Auton T.R., Paolini G.V., and Mee R.P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. Journal of Computer-Aided Molecular Desings 11 (1997) 425-445
23. Karch S.B. The Pathology of Drug Abuse. second ed. (1996), CRC Press
24. Jenkins A.J., Oyler J.M., and Cone E.J. Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. Journal of Analytical Toxicology 19 (1995) 359-374
25. Kamei H., Shimazaki K., and Nishi Y. Computational 3-D modeling and site-directed mutation of an antibody that binds Neu2en5Ac, a transition state analogue of a sialic acid. Proteins 45 (2001) 285-296
26. Sivasubramanian A., Chao G., Pressler H.M., Wittrup K.D., and Gray J.J. Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. Structure 14 (2006) 401-414
27. Sivasubramanian A., Maynard J.A., and Gray J.J. Modeling the structure of mAb 14B7 bound to the anthrax protective antigen. Proteins 70 (2008) 218-230
28. Larsen N.A., Zhou B., Heine A., Wirsching P., Janda K.D., and Wilson I.A. Crystal structure of a cocaine-binding antibody. Journal of Molecular Biology 311 (2001) 9-15
29. Zhu X., Dickerson T.J., Rogers C.J., Kaufmann G.F., Mee J.M., McKenzie K.M., Janda K.D., and Wilson I.A. Complete reaction cycle of a cocaine catalytic antibody at atomic resolution. Structure 14 (2006) 205-216
30. Fishwild D.M., O'Donnell S.L., Bengoechea T., Hudson D.V., Harding F., Bernhard S.L., Jones D., Kay R.M., Higgins K.M., Schramm S.R., and Lonberg N. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nature Biotechnology 14 (1996) 845-851
31. Bruccoleri R.E., and Karplus M. Prediction of the folding of short polypeptide segments by uniform conformational sampling. Biopolymers 26 (1987) 137-168
32. Guex N., and Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18 (1997) 2714-2723
33. Lovell S.C., Davis I.W., Arendall III W.B., de Bakker P.I., Word J.M., Prisant M.G., Richardson J.S., and Richardson D.C. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins 50 (2003) 437-450
34. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., Murray L.W., Arendall III W.B., Snoeyink J., Richardson J.S., and Richardson D.C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Research 35 (2007) W375-W383
35. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., and Taylor R.D. Improved protein-ligand docking using GOLD. Proteins 52 (2003) 609-623
36. Cole J.W.M.N.J.C., and Taylor R. Protein-ligand docking and virtual screening with GOLD. In: Shoichet J.A.B. (Ed). Virtual Screening in Drug Discovery (2005), CRC Press, Boca Raton, Florida, USA